Efficacy of Tocilizumab in COVID-19: Single-Center Experience
COVID-19에서 Tocilizumab의 효능: 단일 센터 경험
Research Article
[키워드] addition
Admission
age
Alanine
alanine aminotransferase
appear
C-reactive protein
Comorbidity
Course
COVID-19
COVID-19 patient
CRP
cut-off value
Cytokine release syndrome
D-dimer
Diagnosis
diagnosis of COVID-19
dimer
duration of symptom
effective
Effectiveness
Efficacy
experience
ferritin
Fever
first dose
Gender
hospital
Hospitalization
Hospitalized
include
intensive care
intensive care unit
Laboratory
lymphocyte
Lymphocyte count
lymphocyte counts
male
median age
mortality group
no difference
oxygen
oxygen demand
Patient
required
Result
Retrospective study
saturation
significantly lower
start time
statistically significant difference
survival group
survived
survivor
syndrome
TCZ
the mean
the mortality group
the patient
Tocilizumab
training
treated
Treatment
two groups
underlying diseases
university
were recorded
while
[DOI] 10.1155/2021/1934685 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1155/2021/1934685 PMC 바로가기 [Article Type] Research Article